Previous close | 2.9933 |
Open | 0.0000 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.0000 - 0.0000 |
52-week range | |
Volume | |
Avg. volume | 21 |
Market cap | 453,628 |
Beta (5Y monthly) | 1.79 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rightsDecember 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753February 29, 20246 075 1056 226 9516 226 702March 29, 20246 075 1056 226 9386 226 689April 30, 20246 075 1056
The study plans for the enrolment of 12 patients in 5 French clinical centersFirst study results expected in Q3 2024This study will enable an evaluation of the intravenous administration of phages, particularly adapted to targeting indications with very high medical stakes. Lyon (France) and Cambridge (MA, US), April 15, 2024 – 7:30am CEST - PHAXIAM Therapeutics (Nasdaq & Euronext: FR0011471135), today announces the enrolment of the 1st patient in the phase 1 clinical study in endocarditis infec
Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rightsDecember 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753February 29, 20246 075 1056 226 9516 226 702March 29, 20246 075 1056 226 9386 226 689 (1) Gross voting rights